Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
about
Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceEfavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsClinical use of HIV integrase inhibitors: a systematic review and meta-analysisAn Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial TherapyTherapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical TrialsWhat's new for antiretroviral treatment in women with HIVSwitching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.HIV integrase inhibitors: a new era in the treatment of HIV.Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood ProductsCritical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Novel approaches to HIV therapy.Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.Inflammation, Immune Activation, and Antiretroviral Therapy in HIVA survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase InhibitorsSingle-Tablet Regimens in HIV TherapyResistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistatAltered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Rapid screening of HIV reverse transcriptase and integrase inhibitors.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.HIV-associated lipodystrophy: impact of antiretroviral therapy.Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsOnce-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionWhat if HIV were unable to develop resistance against a new therapeutic agent?Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.The lifetime medical cost savings from preventing HIV in the United States.Antiretroviral therapy: when to startGenome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093
P2860
Q26783253-7DBB95E1-8289-44EA-9A60-4333EB6F5A7AQ26799712-0CDCE698-5DCC-4B1C-9B0B-2258D5658FCAQ26801286-C8F1BA8E-96AB-41C7-9717-7FFD6C6E2109Q28081266-6D0EE1EC-4540-46EA-ADFE-58CFB3C99E50Q28484930-94AEA0BE-0515-4699-855C-BB0E915C1C55Q28552210-7C216DE8-BBE3-493B-8610-CC87F8070241Q28553571-2DAA297C-8E90-453D-80AC-E9CE474E20F4Q30391322-04050688-21CE-467E-BE8A-DA1099CF4A17Q30795793-276FF5C4-6FB2-400F-888A-44B58815A541Q30956943-A3366F29-8D64-4E22-B0AD-2BD44EED2AD2Q33668385-D681C398-B36A-40A0-B2D2-5A630B984C46Q33680234-C1FF1EA2-9FAE-478F-B52E-41CA0E1D1213Q33767281-F0391048-828A-4847-B9BB-B8D34A238399Q33775397-5709B629-CBAC-42B7-9192-DE2C6475A5D0Q33777819-D70C128D-F807-4EB9-8386-97AFC786E20EQ33817410-CA5E988E-5A18-4522-9A2C-EEB7DC59990AQ33912595-87D9FBA1-4C2A-4465-BC82-6D54C977045FQ33922073-50D88120-4A91-452D-A3C9-DFA6BB147B3BQ33939069-62CDA1BE-846F-49A6-8871-2E85948C60A7Q33939110-A4A58BE9-E659-4C8B-A7C7-7079E3CE5EDAQ33963458-AA891BD6-2DED-4696-B550-53E760BCE3AEQ33997420-ABEF0AED-6423-461F-B0F7-DEB315BEC717Q34059119-159DF207-0E89-4B0A-BBC3-8735252CED3FQ34134900-B802A78B-8913-4F67-9CE6-8C98FE2048D1Q34193340-26C6619A-0345-4F95-95F4-35D6F1BFD2D3Q34478840-A94C3315-D013-433C-A5E7-3C074FE60997Q34655845-15C94395-6F81-427C-B48F-703C2C5C0C7BQ34726183-BE42E437-755C-4512-BF20-2D5DFE9EE900Q34735072-22CEA785-B91E-4017-8E71-600F9C72751AQ34976284-F443BB19-4FE9-4931-A0D9-4A6050A304D5Q35051393-8B995441-D268-4AEA-94EA-F4ED79275150Q35169003-B1E64943-E35C-4D42-94DC-69BE6F79D917Q35177401-8B57CA7C-BDA6-4438-BAFA-A7F12966D5FEQ35204279-A62CA17E-0F59-40F9-94C8-13EB5CD11CDDQ35288691-2DBD48DD-3AD8-4EE8-9686-610B8B6E3397Q35566732-2622B40A-D8D3-4C4A-A84C-1365DAC47068Q35567828-C95A976F-F24E-4BC6-9DFA-0DE158181B4DQ35903617-E4B0FAF1-806C-4582-AB76-3B070228C341Q35965242-7AC13A56-B6D6-4A5A-BDE2-3EBCADB7CCCAQ36157266-57E5C326-57AB-4CA4-B675-5F55C38EBF1E
P2860
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@ast
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@en
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@nl
type
label
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@ast
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@en
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@nl
prefLabel
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@ast
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@en
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@nl
P2093
P3181
P1433
P1476
Co-formulated elvitegravir, co ...... ysis of results after 48 weeks
@en
P2093
Andrew K Cheng
Andrew Zolopa
Anthony Mills
Brian P Kearney
Calvin Cohen
David Wohl
Edwin DeJesus
Erin Quirk
Javier Szwarcberg
P304
P3181
P356
10.1016/S0140-6736(12)60917-9
P407
P577
2012-06-30T00:00:00Z